Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | EDNRB | P24530 | 2/20 | 0.36 |
| ▸ | EDNRA | P25101 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22352966 | 0.83 | GAA (0.36) | ALDH1A1RECQLCA12CA1CA2 | |
| SCHEMBL9320070 | 0.81 | BRD4 (0.51) | ALDH1A1GLASMN1; SMN2CA12CA1 | |
| SCHEMBL19576871 | 0.81 | LMNA (0.41) | ALDH1A1RECQLCA1CA2GAA | |
| SCHEMBL22409314 | 0.80 | ALDH1A1 (0.48) | ALDH1A1GLASMN1; SMN2RECQLGAA | |
| SCHEMBL9320641 | 0.80 | MEN1 (0.52) | ALDH1A1GLASMN1; SMN2CA12CA1 | |
| SCHEMBL24797789 | 0.80 | PARG (0.43) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL20807647 | 0.78 | NSD2 (0.45) | ALDH1A1SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL29404594 | 0.78 | ALDH1A1 (0.46) | ALDH1A1GLASMN1; SMN2RECQLCA12 | |
| SCHEMBL29404344 | 0.78 | ALDH1A1 (0.56) | ALDH1A1GLASMN1; SMN2RECQLCA1 | |
| SCHEMBL22409206 | 0.78 | ALDH1A1 (0.46) | ALDH1A1GLASMN1; SMN2RECQLCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360120-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-3938358-B1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-114072390-B | RAD51 inhibitors | 赛泰尔治疗公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11932636-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220259198-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2022-08-18 | — | — | US | disclosed |
| CN-114072390-A | RAD51 inhibitors | 赛泰尔治疗公司 | 2022-02-18 | — | — | CN | disclosed |
| US-11247988-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247988-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200291014-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200291014-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2020-09-17 | — | — | US | disclosed |
| WO-2020186006-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247988-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | ALDH1A1 4493/4885GLA 3415/4885SMN1; SMN2 245/4885 |
| US-20220259198-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | ALDH1A1 4493/4885GLA 3415/4885SMN1; SMN2 245/4885 |
| US-20200291014-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | ALDH1A1 4493/4885GLA 3415/4885SMN1; SMN2 245/4885 |
| US-20240360120-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | ALDH1A1 4493/4885GLA 3415/4885SMN1; SMN2 245/4885 |
| US-11932636-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | ALDH1A1 4493/4885GLA 3415/4885SMN1; SMN2 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.